OLYS Pharma
The computed 12-month bankruptcy probability of OLYS Pharma is 1.3% (low). The 2024 annual accounts show equity of €565k and a net result of €534k. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 53% of 46 sector peers (fiscal year 2024). The company has been active since 2020 and the Belgian State Gazette contains no insolvency or warning signals.
| Equity | €565k |
| Net result | €534k |
| Better than sector | 53% |
| Active | 5 yrs |
Exceptional profile, strong across almost every axis.
Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
Unlock the full score breakdown, per-year score history and the indicative credit limit with Plus.
See plans →| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 54.7% | 46.9% | |
| Net result | €534k | €-1k | |
| Equity | €565k | €108k | |
| Gross operating margin | €635k | €28k | |
| Total assets | €1.03M | €284k |
| Fiscal year | 2024 |
|---|---|
| Revenue | - |
| EBITDA | €635k |
| Net profit | €534k |
| Cash flow | €623k |
| Staff costs | €-20 |
| Income taxes | - |
| Dividends | - |
| Total assets | €1.03M |
| Equity | €565k |
| Debt | €468k |
| of which ≤ 1y | €268k |
| of which > 1y | €200k |
| Working capital | €-76k |
| Employees (FTE) | - |
| 2024 | |
|---|---|
| Current ratio | 0.72 |
| Quick ratio | 0.69 |
| Working capital ratio | -7.3% |
| Solvency | 54.7% |
| Debt / equity | 0.83 |
| Long-term debt ratio | 0.35 |
| Interest coverage | 38.48 |
| Gross margin | - |
| Net margin | - |
| ROA | 51.7% |
| ROE | 94.5% |
| EBITDA margin | - |
| Days sales outstanding | - |
| Days payable outstanding | - |
| Inventory turnover | - |
| Days inventory (DSI) | - |
| Line item | Code | 2024 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €1.03M |
| Fixed assets | 21/28 | €840k |
| Formation expenses | 20 | €228 |
| Intangible fixed assets | 21 | €840k |
| Tangible fixed assets | 22/27 | €408 |
| Current assets | 29/58 | €192k |
| Stocks & contracts in progress | 3 | €7k |
| Amounts receivable within one year | 40/41 | €18k |
| Cash & bank | 54/58 | €167k |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €1.03M |
| Equity | 10/15 | €565k |
| Contributions / capital | 10/11 | €496k |
| Accumulated profits (losses) | 14 | €-106k |
| Amounts payable | 17/49 | €468k |
| Amounts payable after one year | 17 | €200k |
| Amounts payable within one year | 42/48 | €268k |
| Trade debts payable within one year | 44 | €17k |
| Income statement | ||
| Gross operating margin | 9900 | €635k |
| Operating result | 9901 | €545k |
| Financial income | 75 | €5k |
| Financial charges | 65 | €16k |
| Result before taxes | 9903 | €534k |
| Net result for the period | 9904 | €534k |
| Result to be appropriated | 9905 | €534k |
| NACE primary | 21201 |
| Legal form | Private limited company(610) |
| Incorporation | 25-09-2020 |
| Status | Active |
| Postal code | 1310 |
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 25050F0026/00P017 | Wallonia | 1,390 m² | 1 · 394 m² | 14.5 m · 3 fl. |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
08-08-2024 Articles of association amended, translation of the articles, coordination of the articles and amendment of specific articles
Technical details
{
"notary": {
"name": "David REMY",
"firm_city": null,
"firm_name": null,
"office_city": "Fernelmont",
"is_associated": false
},
"act_meta": {
"language": "mixed",
"pub_date": "2024-08-08",
"filing_date": "2024-08-06",
"act_kind_objet": "STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS), DIVERS"
},
"decision": {
"body": "enig_aandeelhouder_schriftelijk",
"act_date": "2024-07-18",
"unanimous": true
},
"statute_change": {
"kinds": [
"translation",
"coordination",
"targeted_amendment"
],
"scope": "full_restatement",
"trigger": "wvv_adaptation",
"language_after": "nl",
"language_before": "fr"
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "0754.895.372",
"name_full_after": "OLYS Pharma",
"legal_form_after": "Soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e",
"name_full_before": "OLYS Pharma",
"current_zetel_raw": "Chemin de l\u0027Yerne(VER) 6 B : 4537 Verlaine",
"legal_form_before": "Soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e"
},
"special_mandates": [
{
"holder_kbo": "0538.839.354",
"holder_name": "SPREDS FINANCE",
"scope_categories": [
"kbo"
],
"with_substitution": true
},
{
"holder_kbo": null,
"holder_name": "Monsieur VAN HOVE Pascal Urbain",
"scope_categories": [
"kbo"
],
"with_substitution": true
},
{
"holder_kbo": null,
"holder_name": "Madame DE GROOTE Ilse Leonce",
"scope_categories": [
"kbo"
],
"with_substitution": true
}
],
"articles_modified": [
{
"summary": "Article 5 replaced with a new text detailing the issuance of 2,161,000 shares distributed across five categories (A, B1, B2, B3, C1) in exchange for contributions, with each share granting equal rights in profit and liquidation distribution.",
"new_text": "Article 5. Apports\nEn r\u00E9mun\u00E9ration des apports, 2.161.000 actions ont \u00E9t\u00E9 \u00E9mises, r\u00E9parties en 5 cat\u00E9gories :\n \u2022 1.680.000 actions de cat\u00E9gorie A (FONDATEURS) ;\n \u2022 255.000 actions de cat\u00E9gorie B1 (SPREDS FINANCE \u2013 Crowdfunding du d\u00E9part avec Tax\nShelter) ;\n \u2022 21.500 actions de cat\u00E9gorie B2 (SPREDS FINANCE \u2013 Droit de Pr\u00E9f\u00E9rence avec Tax Shelter) ;\n \u2022 180.000 actions de cat\u00E9gorie B3 (Investisseurs a",
"change_kind": "replaced",
"article_title": "Apports",
"article_number": "5"
}
],
"governance_change": null,
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": "David REMY",
"org_rep_person_name": null
},
"co_filed_documents": [
"Bijlagen bij het Belgisch Staatsblad - 08/08/2024 - Annexes du Moniteur belge"
],
"shareholder_rights": {
"quorum_rules_changed": false,
"liquidation_preference_text": null,
"voorkeurrecht_rules_changed": true,
"aandelenoverdracht_restrictions_changed": false
},
"voorwerp_change_summary": null,
"capital_structure_change": {
"operations": [
"share_cancellation",
"share_class_creation",
"capital_increase_cash"
],
"split_ratio": null,
"shares_after": 2161000,
"shares_before": 1935000,
"capital_after_eur": null,
"capital_before_eur": null,
"share_classes_after": [
{
"count": 1680000,
"label": "A",
"rights_summary": "FONDATEURS",
"voting_per_share": 1.0
},
{
"count": 255000,
"label": "B1",
"rights_summary": "SPREDS FINANCE \u2013 Crowdfunding du d\u00E9part avec Tax Shelter",
"voting_per_share": 1.0
},
{
"count": 21500,
"label": "B2",
"rights_summary": "SPREDS FINANCE \u2013 Droit de pr\u00E9f\u00E9rence avec Tax Shelter",
"voting_per_share": 1.0
},
{
"count": 180000,
"label": "B3",
"rights_summary": "Investisseurs avec Tax Shelter",
"voting_per_share": 1.0
},
{
"count": 24500,
"label": "C1",
"rights_summary": "SPREDS FINANCE \u2013 Droit de pr\u00E9f\u00E9rence sans Tax Shelter et investisseurs sans Tax Shelter",
"voting_per_share": 1.0
}
]
},
"coordinated_text_lineage": {
"previous_ag_date": "2020-12-21",
"previous_mb_reference": "21314908"
}
}06-09-2022 Registered office moved to Verlaine
- I'Yverne 6-B à 4537 Verlaine
Technical details
{
"events": [
{
"kind": "zetel_transfer",
"seat_type": "siege_social",
"new_address": {
"raw": "I\u0027Yverne 6-B \u00E0 4537 Verlaine",
"city": "Verlaine",
"region": "waals_gewest",
"street": "Chemin de",
"country": "BE",
"postcode": "4537",
"box_number": null,
"street_number": "6-B",
"locality_suffix": null
},
"old_address": null,
"effective_date": "2022-06-01",
"evidence_quote": "L\u0027assembl\u00E9e g\u00E9n\u00E9rale extraordinaire du 25 mai 2022 a d\u00E9cid\u00E9 de transf\u00E9rer le si\u00E8ge social au Chemin de I\u0027Yverne 6-B \u00E0 4537 Verlaine avec effet au 1er juin.",
"region_changed": false,
"is_statute_change": true,
"nationality_change": false,
"old_address_source": "inferred",
"statute_clause_text": null,
"statute_article_number": null,
"effective_date_qualifier": "absolute",
"statutaire_vs_werkelijke": "statutaire",
"linguistic_region_changed": false,
"court_jurisdiction_changed": false,
"effective_date_is_approximate": false
}
],
"notary": {
"name": null,
"firm_city": null,
"firm_name": null,
"office_city": null,
"is_associated": false
},
"act_meta": {
"language": "mixed",
"pub_date": null,
"filing_date": "2022-05-25",
"act_kind_objet": "Objet de l\u0027acte:"
},
"decision": {
"body": "buitengewone_algemene_vergadering",
"date": "2022-05-25",
"unanimous": null
},
"subject_company": {
"kbo": "0754.895.372",
"name_full": "OLYS Pharma",
"legal_form": "SRL",
"_kbo_filled_from_list": true
},
"publication_proxy": {
"kind": "org",
"org_kbo": null,
"org_name": "ACERTA Guichet d\u0027entreprises ASBL",
"person_name": null,
"org_rep_person_name": "Toon Huybrechts",
"person_role_at_subject": null
},
"co_filed_documents": [
"Bijlagen bij het Belgisch Staatsblad",
"Anmexes du Moniteur belge"
]
}Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
| Legal nameFR | OLYS Pharma |